Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ProQR Therapeutics N.V. (NASDAQ:PRQR), Biomerica, Inc. (NASDAQ:BMRA), VEREIT Inc. (NYSE:VER), Apergy Corporation (NYSE:APY), Zendesk, Inc. (NYSE:ZEN), and Arcus Biosciences, Inc. (NYSE:RCUS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

PRQR DOWNLOAD: http://MarketSourceResearch.com/register/?so=PRQR
BMRA DOWNLOAD: http://MarketSourceResearch.com/register/?so=BMRA
VER DOWNLOAD: http://MarketSourceResearch.com/register/?so=VER
APY DOWNLOAD: http://MarketSourceResearch.com/register/?so=APY
ZEN DOWNLOAD: http://MarketSourceResearch.com/register/?so=ZEN
RCUS DOWNLOAD: http://MarketSourceResearch.com/register/?so=RCUS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine ProQR Therapeutics N.V. (NASDAQ:PRQR), Biomerica, Inc. (NASDAQ:BMRA), VEREIT Inc. (NYSE:VER), Apergy Corporation (NYSE:APY), Zendesk, Inc. (NYSE:ZEN), and Arcus Biosciences, Inc. (NYSE:RCUS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 14th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

PROQR THERAPEUTICS N.V. (PRQR) REPORT OVERVIEW

ProQR Therapeutics N.V's Recent Financial Performance

Analysts expect earnings to be released on February 27th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.46. The estimated EPS forecast for the next fiscal year is -$1.75 and is expected to report on February 27th, 2019.

To read the full ProQR Therapeutics N.V. (PRQR) report, download it here: http://MarketSourceResearch.com/register/?so=PRQR

-----------------------------------------

BIOMERICA, INC. (BMRA) REPORT OVERVIEW

Biomerica's Recent Financial Performance

For the three months ended August 31st, 2018 vs August 31st, 2017, Biomerica reported revenue of $1.27MM vs $1.44MM (down 11.88%) and analysts estimated basic earnings per share -$0.05 vs -$0.02. For the twelve months ended May 31st, 2018 vs May 31st, 2017, Biomerica reported revenue of $5.56MM vs $5.79MM (down 3.93%) and analysts estimated basic earnings per share -$0.17 vs -$0.11. Analysts expect earnings to be released on January 15th, 2019. The report will be for the fiscal period ending November 30th, 2018. Reported EPS for the same quarter last year was -$0.03. The estimated EPS forecast for the next fiscal year is -$0.32 and is expected to report on August 29th, 2019.

To read the full Biomerica, Inc. (BMRA) report, download it here: http://MarketSourceResearch.com/register/?so=BMRA

-----------------------------------------

VEREIT INC. (VER) REPORT OVERVIEW

VEREIT's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, VEREIT reported revenue of $313.87MM vs $306.54MM (up 2.39%) and analysts estimated basic earnings per share -$0.09 vs $0.00. For the twelve months ended December 31st, 2017 vs December 31st, 2016, VEREIT reported revenue of $1,252.29MM vs $1,335.45MM (down 6.23%) and analysts estimated basic earnings per share -$0.04 vs -$0.29. Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.18. The estimated EPS forecast for the next fiscal year is $0.70 and is expected to report on February 28th, 2019.

To read the full VEREIT Inc. (VER) report, download it here: http://MarketSourceResearch.com/register/?so=VER

-----------------------------------------

APERGY CORPORATION (APY) REPORT OVERVIEW

Apergy's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Apergy reported revenue of $316.47MM vs $258.65MM (up 22.35%) and basic earnings per share $0.33 vs $0.24 (up 37.50%). Analysts expect earnings to be released on January 29th, 2019. The report will be for the fiscal period ending December 31st, 2018. The estimated EPS forecast for the next fiscal year is $1.61 and is expected to report on January 29th, 2019.

To read the full Apergy Corporation (APY) report, download it here: http://MarketSourceResearch.com/register/?so=APY

-----------------------------------------

ZENDESK, INC. (ZEN) REPORT OVERVIEW

Zendesk's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Zendesk reported revenue of $154.83MM vs $112.27MM (up 37.91%) and analysts estimated basic earnings per share -$0.32 vs -$0.26. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Zendesk reported revenue of $430.49MM vs $312.00MM (up 37.98%) and analysts estimated basic earnings per share -$1.11 vs -$1.11. Analysts expect earnings to be released on February 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.24. The estimated EPS forecast for the next fiscal year is -$0.95 and is expected to report on February 5th, 2019.

To read the full Zendesk, Inc. (ZEN) report, download it here: http://MarketSourceResearch.com/register/?so=ZEN

-----------------------------------------

ARCUS BIOSCIENCES, INC. (RCUS) REPORT OVERVIEW

Arcus Biosciences' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Arcus Biosciences reported revenue of $4.29MM vs $0.16MM (up 2,532.52%) and analysts estimated basic earnings per share -$0.25 vs -$11.86. Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The estimated EPS forecast for the next fiscal year is -$1.93 and is expected to report on February 14th, 2019.

To read the full Arcus Biosciences, Inc. (RCUS) report, download it here: http://MarketSourceResearch.com/register/?so=RCUS

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that’s ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: [email protected]

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.